— Know what they know.
Not Investment Advice

SAGE NASDAQ

Sage Therapeutics, Inc.
1W: -0.9% 1M: -4.4% 3M: +19.1% 1Y: -19.7% 3Y: -74.8% 5Y: -81.6%
$8.68
Last traded 2025-07-31 — delisted
NASDAQ · Healthcare · Biotechnology · $544.9M mcap · 51M float · 4.83% daily turnover · Short 37% of daily vol

Balance Sheet Trends

Total Assets
$547M -38.0% ▼
5Y CAGR: -12.8%
Total Liabilities
$82M -0.7% ▼
5Y CAGR: -10.1%
Shareholders Equity
$465M -41.8% ▼
5Y CAGR: -13.2%
Cash & Investments
$504M -33.0% ▼
5Y CAGR: -13.0%
Total Debt
$12M +129.2% ▲
5Y CAGR: -20.4%
Net Debt
-$69M -5.1% ▼

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$1.7B$294M$163M$71M$81M
Short-Term Investments$438M$1.4B$1.1B$682M$423M
Cash & ST Investments$2.1B$1.7B$1.3B$753M$504M
Net Receivables$0$19M$14M$83M$9M
Inventory$0$0-$64M$0$0
Other Current Assets$23M$0$51M$33M$18M
Total Current Assets$2.1B$1.8B$1.3B$869M$531M
Property, Plant & Equip.$32M$19M$13M$6M$12M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$2M$1M$1M$0$0
Other Non-Current Assets$3M$4M$69M$7M$4M
Total Non-Current Assets$37M$25M$84M$13M$16M
Total Assets$2.2B$1.8B$1.4B$882M$547M
— Liabilities —
Accounts Payable$4M$10M$19M$10M$13M
Short-Term Debt$9M$7M$8M$0$0
Deferred Revenue$0$0$0$0$0
Other Current Liabilities$32M$41M$36M$21M$15M
Total Current Liabilities$67M$85M$99M$83M$72M
Long-Term Debt$19M$11M$4M$0$0
Other Non-Current Liab.-$19M-$11M-$4M$0$0
Total Non-Current Liabilities$20M$11M$5M$0$11M
Total Liabilities$87M$96M$104M$83M$82M
— Equity —
Common Stock$6K$6K$6K$6K$6K
Retained Earnings-$1.0B-$1.5B-$2.0B-$2.6B-$3.0B
Accumulated OCI$415K-$3M-$10M-$814K$244K
Total Stockholders Equity$2.1B$1.7B$1.3B$800M$465M
Total Liabilities & Equity$2.2B$1.8B$1.4B$882M$547M
— Key Metrics —
Total Debt$28M$18M$12M$5M$12M
Net Debt-$1.6B-$276M-$151M-$66M-$69M
Total Investments$438M$1.4B$1.1B$682M$423M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms